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Introduction
The Million Women Study is a nationwide collaborative
research project in the UK, the chief aim of which is to
describe the relationship between use of hormone
replacement therapy (HRT) and the risk of various condi-
tions, particularly breast cancer. The study began in May
1996 and the plan is to recruit and follow-up a cohort of
1million women invited to attend the UK National Health
Service Breast Screening Programme (NHSBSP).
The NHSBSP was set up in 1988. Once every 3 years each
woman in the UK aged between 50 and 64 years who is
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Objectives:  To describe the design of the Million Women
Study and the characteristics of the study population.
Study design:  Population-based cohort study of women aged
50–64 in the UK.
Setting:  Women are asked to join the Million Women Study
when they are invited to routine screening for breast cancer at
61 of the screening centres of the UK National Health Service
Breast Screening Programme (NHSBSP). An estimated 71%
of women screened by the NHSBSP return a completed
questionnaire.
Participants:  800000 women were recruited between May
1996 and June 1999, and it is planned that an additional
200000 will be recruited by the year 2000.
Results: The characteristics of the first 121000 women
recruited into the Million Women Study are described here. At
recruitment 33% of the study population were currently using
hormone replacement therapy and 47% had used it at some
time. Over half (54%) had used oral contraceptives, and 18%
were current smokers at the time of recruitment. Before they
were screened 1.4% of the women had been diagnosed with
breast cancer in the past, 6% had a mother with a history of
breast cancer and 3.7% had a sister with a history of breast
cancer. It is estimated that 1 million women will have been
recruited by early in the year 2000, and that by the end of the
year 2002 there will be 5000 screen-detected breast cancers
and 23000 deaths in the cohort, the majority of which will be
attributed to cancer (12600 deaths) and circulatory disease
(8000 deaths).
Conclusions: By the end of the year 2002, the Million Women
Study will have sufficient statistical power to detect relative
risks of 0.8 or less, or of 1.2 or more in current users compared
with never users of hormone replacement therapy for mortality
from breast cancer, colorectal cancer, lung and ovarian cancer,
ischaemic heart disease and stroke.Breast Cancer Research    Vol 1 No 1 The Million Women Study Collaborative Group
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registered with the NHS is sent a letter by the NHSBSP,
offering her routine screening for breast cancer by mam-
mography. About 1 million women are screened annually
by the NHSBSP and about 5000 of them have a breast
cancer detected on mammography [1]. The day-to-day
organization and screening activities are performed by
about 100 separate screening offices throughout the UK,
and the work is monitored and statistics gathered centrally
by a national co-ordinating centre.
The present paper describes the design of the Million
Women Study and the characteristics of the study population.
Methods
The Million Women Study is a population-based cohort
study. Women are recruited when they are invited for
routine breast cancer screening, and the main outcomes to
be examined at follow-up are the incidence of screen-
detected breast cancer and cause-specific mortality.
Attendance at screening
About three-quarters of the women who are invited for
screening by the NHSBSP subsequently attend for mam-
mography [1]. Before the study could be launched, it was
necessary to demonstrate that inviting women to join the
Million Women Study would not reduce uptake of screen-
ing offered by the NHSBSP. During 1994 and 1995 a total
of 6000 women who were due to be invited for breast
cancer screening in Oxford and West London were ran-
domly divided into two groups. One group was sent the
usual invitation for screening and the other group was sent
the study questionnaire, accompanying the usual invita-
tion to screening. Attendance rates for screening were
similar, at 71%, among those who were and were not sent
an accompanying questionnaire [2].
Recruitment procedures
Women are asked to join the Million Women Study by
participating NHSBSP screening centres at the time that
or just before they are sent their usual invitation for
routine breast cancer screening. A questionnaire is
included with each woman’s invitation and, if the woman
wishes to join the study, she is asked to complete the
questionnaire, to give signed permission for follow-up,
and to return the questionnaire at the time she is
screened. A freephone number is provided for women
who have any questions or problems filling out the ques-
tionnaire. The questionnaire is four pages long (A4 size)
and includes questions about lifestyle and sociodemo-
graphic factors, reproductive history, past use of oral con-
traceptives, use of HRT, past medical history and family
history of breast cancer. Completed questionnaires are
transferred periodically from the participating screening
centres to the study co-ordinating centre at the Imperial
Cancer Reasearch Fund Cancer Epidemiology Unit
(CEU), Oxford, UK.
Data storage, entry and checking
The confidential completed questionnaires are stored
securely at all times. Once they reach the CEU they are
checked and coded by trained staff and then scanned elec-
tronically. The scanned data are ‘captured’ using comput-
erized intelligent character recognition and optical mark
reading software (Eyes and Hands®; Readsoft Inc, Slough,
UK). Range and logical checks are performed at the time
of data entry. Any inconsistency or information that is not
recognised by the data capture software is verified manu-
ally by trained data entry staff, who also validate com-
puter-interpreted data and check each questionnaire to
confirm whether signed consent for follow up has been
granted. Each week the verified data for about 50 individ-
uals are checked against the original questionnaires and
the error rate is consistently below 1%. This partially auto-
mated process thus permits data to be entered rapidly and
with high accuracy.
Follow up for breast cancer
Each screening centre of the NHSBSP is required to
compile annual statistics on its activities, which include
details of all breast cancers detected at mammography [1].
A list of women enrolled into the Million Women Study at
each centre is cross-checked at regular intervals against the
list of the women diagnosed with screen-detected breast
cancer at that centre. If a breast cancer has been diagnosed
at screening in a study participant, routinely recorded
details of the cancer are abstracted, including tumour loca-
tion, histology, size, grade, invasive status and involvement
of axillary lymph nodes. Information on hormone receptor
status and treatment is abstracted when it is available.
Several approaches are being used to identify breast
cancers diagnosed subsequent to screening. One will
involve record linkage with cancer registry data. Also,
women will be contacted directly 2–3 years after they were
screened, and asked about new illnesses, including any
new breast cancers, that may have been diagnosed (see
Additional follow up, below). This will permit the identifi-
cation of both screen-detected and interval cancers.
Follow up for deaths
Deaths are identified annually by computerized matching
of name, date of birth and NHS number of the women
who gave signed consent for follow up in the Million
Women Study, with the national death files held by the
Office of National Statistics. For each death thus identi-
fied the date of death and underlying and associated
causes of death are provided by the Office of National
Statistics.
Additional follow up
Participants will be sent a follow-up questionnaire about
2–3 years after recruitment, to ascertain changes in use of
HRT and incident morbidity, for example breast cancers,
diagnosed outside the screening programme.75
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Validation
The most important variables for this study are the sub-
jects’ identification details, their use of HRT, any diagno-
sis of breast cancer and the recording of deaths. To assess
the accuracy of the subjects’ identification details and of
the recording of deaths, a random sample of 5000 women
recruited in 1996 has been selected for flagging on the
NHS Central Register (NHSCR). Identification details
recorded for the study (name, address, date of birth and
NHS number) enabled all but 10 (0.2%) of the 5000
women to be identified on the NHSCR. The complete-
ness and accuracy of the reported deaths will be validated
in the future against those recorded in the NHSCR for
these 5000 women.
The reliability of diagnosis of screen-detected breast
cancers is monitored by various quality control procedures
within the NHSBSP. Screen-detected breast cancers are
verified according to defined procedures, and the invasive
status, size and type of cancer are recorded for virtually
100% of the cancers.
The validity of reported information on use of HRT,
including the type and dose, is being examined and a full
report will be published in due course. Preliminary com-
parisons with the prescription records from one general
practice in Oxfordshire indicate at least 95% agreement
for reported current use of HRT, including the hormonal
constituents of the preparation used most recently (Banks
et al, unpublished data).
Results
After it was demonstrated that the Million Women Study
questionnaire did not alter attendance rates [2], each
screening centre in England, Scotland and Wales was
invited to participate in the study. Almost all the centres
expressed enthusiasm for the study, although practical
problems precluded the involvement of some centres.
The most frequent reason for screening centres not partic-
ipating was that the Million Women Study questionnaire
could not readily be packaged together with the letters
and other information normally posted to women when
they are invited for screening.
Accrual of the cohort
Recruitment of women into the study began in May 1996.
Most of the participating screening centres began recruit-
ment during 1997, and 61 centres were taking part by late
1998. The locations of these centres are shown in Fig. 1.
Before recruitment could begin at any centre, local ethical
committee approval was required, and this often entailed
contacting more than one ethical committee for each
centre. In total, 126 local ethical committees were
approached and approval for the study was obtained
without exception.
Figure 2 shows the numbers of questionnaires returned to
the CEU between May 1996 and June 1999. More than
800000 questionnaires had been returned by the middle
of 1999, and according to this accrual rate it is estimated
that a cohort of 1 million women will have been recruited
by early in the year 2000.
Response rate
Statistics presented here are based on the first 227000 ques-
tionnaires, which were printed between May 1996 and Feb-
ruary 1997. This represented a convenient point in the
accrual of women to assess response rate, because the
layout and colour of the questionnaire were modified at this
stage. Table 1 shows the numbers of questionnaires dis-
patched and returned, and whether the respondents also
gave signed permission for follow up. Overall 121000 (53%)
of the questionnaires sent out were returned to the CEU.
Women who returned a questionnaire are referred to as
Figure 1
Location of UK National Health Service Breast Screening Centres
that began recruitment into the Million Women Study before
December 1998.‘respondents’, and it is estimated that they comprise about
71% of the women screened at the participating centres.
Not all respondents can be included in the cohort to be fol-
lowed, however, because 7% of them did not give signed
consent or gave insufficient personal details for follow up.
The remaining 93% of the respondents who can be fol-
lowed are referred to as ‘the cohort’ or as ‘participants’.
Characteristics of 121000 respondents
Table 2 summarizes certain characteristics of the first
121000 respondents, including details of their age, use of
HRT, reproductive history, past use of oral contraceptives
and consumption of cigarettes. It can be seen that most
women are aged between 50 and 64 at recruitment (a
small number of women are screened just before their
50th birthday and women aged over 65 can be screened by
the NHSBSP if they specifically request it). It can also be
seen that for most variables there are little missing data.
One-third (33%) of the women reported currently using
HRT, and almost half (47%) had used it at some time.
More than half (54%) had used oral contraceptives and
18% were current smokers.
Table 3 summarizes the history and family history of
breast disease, including breast cancer, in the respondents:
1.4% of the women had breast cancer diagnosed before
recruitment and 9% reported that their mother and/or
sister(s) had breast cancer diagnosed in the past. Table 4
summarizes the respondents’ history of various other ill-
nesses and operations. It can be seen that a substantial
proportion of women have had hypertension diagnosed or
are being treated for it, that one in four women have had a
hysterectomy, one in five have been sterilized and one in
14 have had a bilateral oophorectomy.
Comparison of participants and nonparticipants
The overwhelming reason for nonparticipation in the
Million Women Study is not attending for breast cancer
screening, having been invited to do so. Women are asked
to bring the completed questionnaire with them when
they are screened, and thus far over 99% of the respon-
dents were recruited in this way. Although no envelope or
pre-paid postage is provided, a small number of the
respondents posted their questionnaire back to the
screening or co-ordinating centre, and virtually all of them
also attended for breast cancer screening.
Breast Cancer Research    Vol 1 No 1 The Million Women Study Collaborative Group
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Table 1
Response rate for the Million Women Study*
Estimated number of women who were sent a questionnaire 227000
when they were invited for screening
Estimated number who were screened 170000 (75% of those invited [1])
Number of women who returned a questionnaire 121129 (53% of those invited and 71% of those screened)
Number of women who returned a questionnaire with full 113104 (50% of those invited, 66% of those screened and
identification details and signed permission for follow up 93% of those returning a questionnaire)
Number of women who returned a questionnaire without full 8025 (3.5% of those invited, 4.7% of those screened and
identification details and/or signed permission for follow up 6.6% of those returning a questionnaire)
*For the first printing of the Million Women Study questionnaire.
Figure 2
Accrual of women into the Million Women Study, up to June 1999.A direct comparison of those who agreed to participate in
the study with those who did not has been performed in
one general practice in Oxfordshire and similar compar-
isons are planned for other areas. A full report of these
findings will be published in the future, but preliminary
results suggest that there are few substantial differences
between participants and nonparticipants. At this stage the
main difference between the groups appears to be that
nonparticipants are more likely than participants to be pre-
scribed medications for the treatment of hypertension
(Banks  et al, unpublished data).
About 7% of the respondents returned the study question-
naire but did not give sufficient information and/or signed
permission for follow up. Table 5 compares their characteris-
tics with those of the 93% who can be followed. It can be
seen that the main difference between these two groups is
that the women who gave consent and sufficient information
to be followed were more likely to be current users of HRT
http://breast-cancer-research.com/vol1no1/19aug99/research/1
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Table 2
Some characteristics of 121000 respondents in the Million
Women Study
Characteristic Percentage
Age at screening (years)
49 4.9
50–54 37.9
55–59 29.1
60–64 25.0
65+ 2.3
Use of hormone replacement therapy
Ever 47.2
Never 51.4
Missing 1.4
Number of children
0 11.3
1 13.1
2 41.7
3 21.8
4 7.8
5 2.5
6+ 1.4
Missing 0.3
Age at birth of first child (years)
<20 12.6
20–24 46.0
25–29 29.0
30–34 8.0
35+ 2.5
Missing 1.8
Past use of oral contraceptives
Yes 53.6
No 44.7
Missing 1.7
Smoking history
Never 50.3
Current 18.1
Ex-smoker 26.4
Missing 5.3
Table 3
History of breast disease, including breast cancer, in 121000
respondents to the Million Women Study and their relatives
Characteristic Percentage
Previous screening for breast cancer
Yes 79.0
No 20.2
Missing 0.8
Previous surgery for breast disease
Yes 12.8
No 86.4
Missing 0.8
Previous breast cancer
Yes 1.4
No 98.0
Missing 0.6
History of maternal breast cancer
Yes 6.0
No 90.7
Not known 2.7
Missing 0.6
History of breast cancer in a sister
Yes 3.7
No 55.1
No sister 38.6
Not known 1.9
Missing 0.8
Table 4
Previous illnesses and conditions for which women are now
being treated in 121000 respondents to the Million Women
Study
Characteristic Percentage
Women with a history of:
Hypertension, when pregnant 23.7
Hypertension, when not pregnant 22.0
Blood clot in leg 4.5
Heart disease 3.8
Diabetes mellitus 2.7
Stroke 1.0
Women currently being treated for:
Hypertension 14.9
Depression/anxiety 9.5
Asthma 7.1
Thyroid disease 5.9
Heart disease 2.6
Diabetes mellitus 2.5
Women with previous operations:
Hysterectomy 25.1
Tubal ligation 19.2
Bilateral oophorectomy 7.4(33 versus 25%) and to have ever used oral contraceptives
(54 versus 45%) than the women who cannot be followed.
Expected numbers and statistical power
At the present accrual rate it is expected that a cohort of 1
million women will have been recruited by the year 2000.
Based on national statistics from the NHSBSP [1], about
5000 screen-detected breast cancers would be expected in
this cohort. Given these numbers, and the expected pro-
portion of current and never users of HRT at recruitment,
the study should have 80% power to detect a relative risk
of 1.1 in both current users and in current users of dura-
tions of at least 5 years, compared with never users.
Another aim of the study is to examine the relationship
between use of HRT and mortality from various causes,
the objective being to present findings with respect to the
most important causes of death within 5 years. Table 6
shows the expected numbers of deaths from various
causes by the end of 2002, assuming that 1 million women
are recruited by the beginning of the year 2000. As with
other cohort studies of women taking hormonal agents [3],
it is likely that mortality in these women will be somewhat
lower than that of the general population because of self-
selection of relatively healthy subjects into the study. The
expected numbers in Table 6 have, therefore, been calcu-
lated assuming that death rates from causes other than
breast cancer are 20% lower than the national rate and that
breast cancer death rates are 30% lower than the national
rate, thus taking into account the additional expected
benefit of screening [4]. It can be seen that by the end of
2002 about 23000 deaths will have occurred, with the
majority being attributed to cancer (12600 deaths) or to
diseases of the circulatory system (8000).
Previous studies have suggested that both recency and
duration of HRT use are important in determining its
effect on breast cancer, and perhaps on other diseases
[5,6]. However, because women tend to stop taking HRT
when they become ill, there are problems in interpreting
differences in mortality according to HRT use at the time
of death. One way of overcoming these problems is to
examine mortality in relation to use of HRT before diag-
nosis of any serious illness. Analyses of cause-specific mor-
tality in relation to use of HRT within the Million Women
Study will, therefore, exclude women with serious ill-
nesses at the time of recruitment and be based on use as
recorded at the time of entry into the cohort.
Table 6 shows the least extreme detectable relative risks
for each of the main causes of death to be examined for
various patterns of HRT use as compared with never
users. These power calculations show that for a common
cancer, such as colorectal cancer, there should be suffi-
cient power to detect an increase or decrease in mortality
of as little as about 20% in current users compared with in
nonusers, and of about 25% in current users of long dura-
tion compared with nonusers. Even for endometrial
cancer, which is the least common of the causes listed, it
should be possible to detect quite modest increases or
decreases in mortality of around 40% in current users com-
pared with never users, and of about 45% in current users
of long durations compared with never users.
By the end of the year 2002, the largest numbers of
expected deaths among these women will be due to breast
cancer and ischaemic heart disease. Thus, the effect of HRT
use on deaths from these two causes will be particularly
important in determining the net benefit or risk to mortality
in HRT users as compared with nonusers. For both of these
conditions relative risks of greater than 1.1 or less than 0.9
would be detectable among current versus never users. The
corresponding figures among current users with durations of
use of 5 or more years are 1.2 and 0.8, respectively.
Other questions
Many other questions about women’s health can also be
answered by this study. The cohort is sufficiently large to
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Table 5
Comparison of those who did and did not give sufficient
information and/or permission for follow up
Sufficient information
and/or
permission for follow up
Characteristic Yes No
(n=113104) (n=8025)
Average age (years) 56.1 56.2
Average age at leaving school (years) 15 15
Average height (m) 1.62 1.62
Average weight (kg) 68.5 67.5
Current smoker (%) 18 18
Drink alcohol (%) 78 72
Exercise at least once a week (%) 43 42
Parous (%) 89 84
Average number of children 2.4 2.4
Average age at first birth (years) 24.0 24.3
Previous breast cancer screen (%) 79 76
Previous diagnosis of breast cancer (%) 1.4 0.9
Mother or sister with a history of breast 9 8
cancer (%)
Previous use of oral contraceptives (%) 54 45
Current use of HRT (%) 33 25
Past use of HRT (%) 15 14
HRT, hormone replacement therapy.provide reliable data on the health effects of many
lifestyle factors, including the consumption of tobacco and
alcohol, and on the effects of past use of other hormonal
agents, such as oral contraceptives. In addition, the
Medical Research Council is supporting an extension of
the study to evaluate the effect of HRT on the efficacy of
mammography. In that study, women recalled for further
assessment after screening and women with interval
cancers are being identified. Information on interval
cancers is being sought from cancer registries and also
directly by sending women a follow-up questionnaire 2–3
years after their initial screen and asking about recent
morbidity, including diagnosis of breast cancer. This will
allow estimation of how HRT affects the sensitivity and
specificity of mammography.
Discussion
The main purpose of the Million Women Study is to
examine the relationship between breast cancer and use of
HRT, in a context where use of hormonal therapy is
recorded as reliably as possible and breast cancers are
diagnosed as uniformly and consistently as possible.
Obtaining details of use of HRT before any breast cancer
is diagnosed will minimise possible reporting biases of use
of such therapy. Moreover, studying screen-detected
breast cancers overcomes the potential bias that women
who are taking HRT may be more likely to be screened
than women who do not use such therapy. The limitation
of examining screen-detected cancers alone, however, is
that use of HRT may itself reduce the efficacy of mammo-
graphic screening. The plan, therefore, is to follow the
women screened for interval breast cancer, and to include
those cancers in the analyses of the relation between use
of HRT and breast cancer.
Because the entire cohort is being followed up for deaths,
it will also be possible to look at the relationship between
use of HRT and mortality from various causes. Women
prescribed HRT tend to be healthier than those who are
not, however, and so it is crucial that analyses take proper
account of the so-called ‘healthy user effect’ [7]. In
designing the study attention has been given to the
recording of detailed information about illnesses present
at the time of recruitment. It can be seen in Tables 3 and
4 that a substantial proportion of women recruited have
had illnesses such as hypertension and other cardiovascu-
lar disease in the past that would affect their risk of death
from circulatory disease and other causes. The plan is to
analyse results separately according to history of previous
illness, and most weight will be given to the findings in
women who had no previous illness.
Randomized clinical trials of HRT are now underway.
These trials will have sufficient statistical power to detect
a substantial reduction in ischaemic heart disease, but will
not be able to pick up important, but modest, changes in
the risk of cancer [7]. Thus, there will be a continued
need for observational data to look at the effects of HRT
on disease.
Conclusion
The Million Women Study is one of the largest cohort
studies ever devised. Recruitment is proceeding rapidly
and the study is on target to accrue a cohort of 1 million
http://breast-cancer-research.com/vol1no1/19aug99/research/1
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Table 6
Estimated number of deaths up to the end of the year 2002 in the Million Women Study cohort and minimum and maximum
detectable relative risks for certain common conditions
Current users of 5+ years duration
Current versus never users versus never users
Expected Minimum Maximum Minimum Maximum
number detectable detectable detectable detectable
Cause of death of deaths* RR† >1 RR † <1 RR † >1 RR † <1
All cancers 12600 1.06 0.94 1.08 0.92
Colorectal cancer 1200 1.20 0.82 1.25 0.77
Lung cancer 2000 1.15 0.86 1.19 0.82
Breast cancer 2800 1.13 0.88 1.16 0.85
Ovarian cancer  1100 1.20 0.81 1.26 0.76
Endometrial cancer 250 1.41 0.65 1.53 0.56
All circulatory disease 8000 1.08 0.93 1.10 0.91
Ischaemic heart disease 5000 1.09 0.91 1.12  0.88
Stroke 1700 1.16 0.85 1.21 0.81
All causes of death 23200 1.05 0.95 1.06 0.94
*Based on national mortality rates for 1996 in England and Wales with
the assumption that death rates from causes other than breast cancer
are 20% lower than the national rate and that breast cancer death
rates are 30% lower than the national rate. †Detectable at the 95%
significance level with 80% power, assuming that death rates among
never users are equivalent to national rates. RR, risk ratio.women by the year 2000. Preliminary results indicate that
the women joining the Million Women Study do not differ
substantially from women of a similar age in the general
population.
It is expected that, within 5 years, the study will have suf-
ficient statistical power to answer questions about the role
of HRT in mortality from breast cancer and other specific
conditions of interest.
This cohort may ultimately include about one woman in
every five aged between 50 and 64 years in the UK. This
excellent co-operation at a national level reflects the effi-
cient organization of the NHSBSP. It is also indicative,
perhaps, of concern by women at the lack of reliable
knowledge about the long-term effects of HRT and the
fact that in the UK today there is substantial use of this
type of therapy.
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